MICHAEL A GIMBRONE, M.D.
Medical Practice at Francis St, Boston, MA

2004008, Apr 29, 2004

Sep 3, 2003

10/653872

Dean Falb - Wellesley MA, US
Michael Gimbrone - Jamaica Plain MA, US

Millennium Pharmaceuticals, Inc.

C12Q001/68, C07H021/04, C12N009/02, C12P021/02, C12N005/06

435/006000, 435/069100, 435/189000, 435/320100, 435/325000, 536/023200

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

2002003, Mar 21, 2002

Jun 6, 1997

08/870434

DEAN A. FALB - WELLESLEY MA, US
Michael Gimbrone - Jamaica Plain MA, US

A61K039/395, C07K017/00, C07K016/00, C07K014/00, G01N033/53, C12Q001/68, C07H021/04, A01N043/04

435/006000, 514/012000, 424/130100, 536/023100, 514/044000, 435/007100, 530/387100, 530/350000

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

6020463, Feb 1, 2000

Oct 6, 1997

8/944423

Dean A. Falb - Wellesley MA
Michael A. Gimbrone - Jamaica Plain MA

Millennium Pharmaceuticals, Inc. - Cambridge MA
Brigham and Women's Hospital - Boston MA

C07K 1600, C12N 1500

530350

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials.

2002010, Aug 1, 2002

Aug 11, 1999

09/372044

DEAN A. FALB - WELLESLEY MA, US
MICHAEL A. GIMBRONE - JAMAICA PLAIN MA, US

G01N033/537, G01N033/543, G01N033/53, C07H021/04, C12P019/34

435/007100, 435/007800, 435/091210, 435/007920, 536/023500

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

2003018, Oct 2, 2003

Jul 2, 2002

10/186950

Dean Falb - Wellesley MA, US
Michael Gimbrone - Jamaica Plain MA, US

Millennium Pharmaceuticals, Inc.

A01K067/00, C12Q001/68, A61K048/00, C07H021/04, C12P021/02, C12N005/06, C07K014/47

800/008000, 435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 514/044000, 536/023500

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

5968770, Oct 19, 1999

Jun 7, 1995

8/485573

Dean A. Falb - Wellesley MA
Michael A. Gimbrone - Jamaica Plain MA

Millennium Pharmaceuticals, Inc. - Cambridge MA

C12N 121

435 691

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials.

5302384, Apr 12, 1994

Feb 25, 1993

8/028705

Michael A. Gimbrone - Jamaica Plain MA
M. Elyse Wheeler - Diamond Head AZ

Brigham and Women's Hospital - Boston MA

A61K 4505

424 852

The present invention relates to intercellular adhesion inhibitory factors produced by cytokine activated endothelial cells. These factors designated endothelial-derived IL-8 find use in the diagnosis and treatment of inflammation and in the protection of endothelial cells from neutrophil mediated damage.

5403713, Apr 4, 1995

Aug 5, 1993

8/102510

Michael P. Bevilacqua - La Jolla CA
Michael A. Gimbrone - Jamaica Plain MA

Brigham & Women's Hospital - Boston MA

A61K 39395, A61K 3944

435 71

The invention relates to a method for detecting ELAM-1 expression in a patient comprising (i) administration of a detectable amount of a labelled ELAM-1 specific antibody (or an anti-ELAM 1 antibody fragment) and a pharmaceutically acceptable carrier, and (ii) detecting the label. ELAM-1 is an endothelial cell surface glycoprotein which participates in endothelialleukocyte adhesion. Induction of ELAM-1 expression has been detected on endothelial cells at sites of inflammation.

5451399, Sep 19, 1995

Oct 19, 1992

7/964525

Michael A. Gimbrone - Jamaica Plain MA
Martin S. Obin - Newton Centre MA
Joffre B. Baker - El Granada CA
Caroline A. Hebert - San Francisco CA

Brigham and Women's Hospital - Boston MA
Genentech, Inc. - South San Francisco CA

A61K 4505, A61K 3700, A61K 3710, C07K 1300

424 852

A novel polypeptide [Ala IL-8]. sub. 77 is provided which is a potent modulator of neutrophil functions. The polypeptide factor and related compositions find use as anti-inflammatory agents and as therapeutics for clinical indications in which damage to vascular endothelium and other tissues occurs. The amino acid and nucleotide sequence of the factor and methods for its purification, recombinant production and pharmaceutical use are provided.